Your browser doesn't support javascript.
loading
Targeting Filamin A Reduces Macrophage Activity and Atherosclerosis.
Bandaru, Sashidar; Ala, Chandu; Salimi, Reza; Akula, Murali K; Ekstrand, Matias; Devarakonda, Sravani; Karlsson, Joakim; Van den Eynden, Jimmy; Bergström, Göran; Larsson, Erik; Levin, Max; Borén, Jan; Bergo, Martin O; Akyürek, Levent M.
Afiliação
  • Bandaru S; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine (S.B., C.A., R.S., S.D., J.V.d.E., E.L., L.M.A.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Ala C; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine (S.B., C.A., R.S., S.D., J.V.d.E., E.L., L.M.A.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Salimi R; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine (S.B., C.A., R.S., S.D., J.V.d.E., E.L., L.M.A.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Akula MK; Sahlgrenska Cancer Center, Sahlgrenska Academy (M.K.A., J.K., M.O.B.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Ekstrand M; Department of Molecular and Clinical Medicine, Institute of Medicine (M.E., G.B., M.L., J.B.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Devarakonda S; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine (S.B., C.A., R.S., S.D., J.V.d.E., E.L., L.M.A.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Karlsson J; Sahlgrenska Cancer Center, Sahlgrenska Academy (M.K.A., J.K., M.O.B.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Van den Eynden J; Department of Surgery, Institute of Clinical Sciences (J.K.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Bergström G; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine (S.B., C.A., R.S., S.D., J.V.d.E., E.L., L.M.A.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Larsson E; Department of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University, Belgium (J.V.d.E.).
  • Levin M; Department of Molecular and Clinical Medicine, Institute of Medicine (M.E., G.B., M.L., J.B.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Borén J; Region Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Physiology, Göteborg, Sweden (G.B.).
  • Bergo MO; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine (S.B., C.A., R.S., S.D., J.V.d.E., E.L., L.M.A.), Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Akyürek LM; Department of Molecular and Clinical Medicine, Institute of Medicine (M.E., G.B., M.L., J.B.), Sahlgrenska Academy, University of Gothenburg, Sweden.
Circulation ; 140(1): 67-79, 2019 07 02.
Article em En | MEDLINE | ID: mdl-31014088
ABSTRACT

BACKGROUND:

The actin-binding protein FLNA (filamin A) regulates signal transduction important for cell locomotion, but the role of macrophage-specific FLNA during atherogenesis has not been explored.

METHODS:

We analyzed FLNA expression in human carotid atherosclerotic plaques by immunofluorescence. We also produced mice with Flna-deficient macrophages by breeding conditional Flna-knockout mice ( Flna o/fl) with mice expressing Cre from the macrophage-specific lysosome M promoter ( LC). Atherosclerosis in vivo was studied by transplanting bone marrow from male Flna o/fl/ LC mice to atherogenic low-density lipoprotein receptor-deficient ( Ldlr-/-) mice; and by infecting Flna o/fl and Flna o/fl/ LC mice with AdPCSK9 (adenoviral vector overexpressing proprotein convertase subtilisin/kexin type 9). Furthermore, C57BL/6 mice were infected with AdPCSK9 and then treated with the calpain inhibitor calpeptin to inhibit FLNA cleavage.

RESULTS:

We found that macrophage FLNA expression was higher in advanced than in intermediate human atherosclerotic plaques. Flna o/fl/ LC macrophages proliferated and migrated less than controls; expressed lower levels of phosphorylated AKT and ERK1/2; exhibited reduced foam cell formation and lipid uptake; and excreted more lipids. The deficiency of Flna in macrophages markedly reduced the size of aortic atherosclerotic plaques in both Ldlr-/-BMT Flnao/fl/LC and AdPCSK9-infected Flna o/fl/ LC mice. Intima/media ratios and numbers of CD68-positive macrophages in atherosclerotic plaques were lower in Flna-deficient mice than in control mice. Moreover, we found that STAT3 interacts with a calpain-cleaved carboxyl-terminal fragment of FLNA. Inhibiting calpain-mediated FLNA cleavage with calpeptin in macrophages reduced nuclear levels of phosphorylated STAT3, interleukin 6 secretion, foam cell formation, and lipid uptake. Finally, calpeptin treatment reduced the size of atherosclerotic plaques in C57BL/6 mice infected with AdPCSK9.

CONCLUSIONS:

Genetic inactivation of Flna and chemical inhibition of calpain-dependent cleavage of FLNA impaired macrophage signaling and function, and reduced atherosclerosis in mice, suggesting that drugs targeting FLNA may be useful in the treatment of atherosclerosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Marcação de Genes / Aterosclerose / Filaminas / Ativação de Macrófagos Limite: Animals / Humans / Male Idioma: En Revista: Circulation Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Marcação de Genes / Aterosclerose / Filaminas / Ativação de Macrófagos Limite: Animals / Humans / Male Idioma: En Revista: Circulation Ano de publicação: 2019 Tipo de documento: Article